Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunomedics (IMMU)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adaptimmune Therapeutics (NASDAQ:ADAP) and Immunomedics (NASDAQ:IMMU) with bullish sentiments.

Adaptimmune Therapeutics (ADAP)

In a report released today, Marc Frahm from Cowen & Co. assigned a Buy rating to Adaptimmune Therapeutics. The company’s shares opened today at $11.10.

According to TipRanks.com, Frahm is ranked #3199 out of 4840 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adaptimmune Therapeutics with a $19 average price target, implying a 71.2% upside from current levels. In a report released today, Raymond James also maintained a Buy rating on the stock.

.

See today’s analyst top recommended stocks >>

Immunomedics (IMMU)

Cowen & Co. analyst Phil Nadeau assigned a Buy rating to Immunomedics today and set a price target of $30. The company’s shares opened today at $25.69, close to its 52-week high of $27.33.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 15.8% and a 58.1% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Immunomedics is a Strong Buy with an average price target of $36, implying a 40.1% upside from current levels. In a report issued on July 9, Jefferies also reiterated a Buy rating on the stock with a $30 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts